1st RDEB patient in US to soon receive gene therapy Zevaskyn
The first recessive dystrophic epidermolysis bullosa (RDEB) patient will be dosed with the cell-based gene therapy Zevaskyn (prademagene zamikeracel) in the next few months, with several others lined up to follow, according to developer Abeona Therapeutics. That patient has already been selected, and their skin cells have been…